The Role of Invariant Natural Killer T Cells in Cancer

References (147)

1. 1 Angiogenesis in health and disease [DOI]
2. 2 Tumour-educated macrophages promote tumour progression and metastasis [DOI]
3. 3 NKT cells: what's in a name? [DOI]
4. 4 NKT cells: facts, functions and fallacies [DOI]
5. 5 NKT cell–mediated repression of tumor immunosurveillance by IL-13 and the IL-4R–STAT6 pathway [DOI]
6. 6 Prolonged IFN-γ–producing NKT response induced with α-galactosylceramide–loaded DCs [DOI]
7. 7 A Subset of CD4 + Thymocytes Selected by MHC Class I Molecules [DOI]
8. 8 CD1d-restricted iNKT cells, the ‘Swiss-Army knife’ of the immune system [DOI]
9. 9 Loss of IFN-γ Production by Invariant NK T Cells in Advanced Cancer [DOI]
10. 10 KRN7000, a novel immunomodulator, and its antitumor activities.
11. 11 Homotypic Interactions Mediated by Slamf1 and Slamf6 Receptors Control NKT Cell Lineage Development [DOI]
12. 12 The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion [DOI]
13. 13 Chapter 8 The Role of NKT Cells in Tumor Immunity [DOI]
14. 14 Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model [DOI]
15. 15 A Phase I-II Study of α-Galactosylceramide-Pulsed IL-2/GM-CSF-Cultured Peripheral Blood Mononuclear Cells in Patients with Advanced and Recurrent Non-Small Cell Lung Cancer [DOI]
16. 16 Myeloid Suppressor Cell Depletion Augments Antitumor Activity in Lung Cancer [DOI]
17. 17 Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma [DOI]
18. 18 Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy [DOI]
19. 19 Development and Function of Invariant Natural Killer T Cells Producing TH2- and TH17-Cytokines [DOI]
20. 20 NKT cells: T lymphocytes with innate effector functions [DOI]
21. 21 A novel function of Valpha14+CD4+NKT cells: stimulation of IL-12 production by antigen-presenting cells in the innate immune system.
22. 22 PD-1/PD-L Blockade Prevents Anergy Induction and Enhances the Anti-Tumor Activities of Glycolipid-Activated Invariant NKT Cells [DOI]
23. 23 IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity [DOI]
24. 24 The 5TMM series: a useful in vivo mouse model of human multiple myeloma [DOI]
25. 25 How invariant natural killer T cells respond to infection by recognizing microbial or endogenous lipid antigens [DOI]
26. 26 Galactose‐modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis [DOI]
27. 27 Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells [DOI]
28. 28 CD1d-Restricted NKT Cells: An Interstrain Comparison [DOI]
29. 29 Cutting Edge: Analysis of Human Vα24+CD8+ NK T Cells Activated by α-Galactosylceramide-Pulsed Monocyte-Derived Dendritic Cells [DOI]
30. 30 IFN-gamma-mediated inhibition of tumor angiogenesis by natural killer T-cell ligand, alpha-galactosylceramide.
31. 31 Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice.
32. 32 Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse [DOI]
33. 33 Cutting Edge: A Major Fraction of Human Bone Marrow Lymphocytes Are Th2-Like CD1d-Reactive T Cells That Can Suppress Mixed Lymphocyte Responses [DOI]
34. 34 Impaired Proliferative Response of Vα24 NKT Cells from Cancer Patients Against α-Galactosylceramide [DOI]
35. 35 Enrichment of Human CD4+ Vα24/Vβ11 Invariant NKT Cells in Intrahepatic Malignant Tumors [DOI]
36. 36 Cutting Edge: Nonglycosidic CD1d Lipid Ligands Activate Human and Murine Invariant NKT Cells [DOI]
37. 37 Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow [DOI]
38. 38 Invariant natural killer T cells: innate‐like T cells with potent immunomodulatory activities [DOI]
39. 39 The Microenvironment and Molecular Biology of the Multiple Myeloma Tumor [DOI]
40. 40 Multiple Myeloma Macrophages: Pivotal Players in the Tumor Microenvironment [DOI]
41. 41 Identification of novel glycolipid ligands activating a sulfatide‐reactive, CD1d‐restricted, type II natural killer T lymphocyte [DOI]
42. 42 Structure-Activity Relationship Studies of Novel Glycosphingolipids That Stimulate Natural Killer T-Cells [DOI]
43. 43 Depletion of CD4+CD25+ regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model [DOI]
44. 44 Regulation of Immune Responses by CD1d-Restricted Natural Killer T Cells [DOI]
45. 45 IFN-γ-Producing Human Invariant NKT Cells Promote Tumor-Associated Antigen-Specific Cytotoxic T Cell Responses [DOI]
46. 46 Interaction Between Invariant NKT Cells and Myeloid-derived Suppressor Cells in Cancer Patients [DOI]
47. 47 The 5T2MM Murine Model of Multiple Myeloma: Maintenance and Analysis [DOI]
48. 48 Beta‐Glucosylceramide Administration (i.p.) Activates Natural Killer T cells In Vivo and Prevents Tumor Metastasis in Mice [DOI]
49. 49 CD1d-restricted mouse Vα14 and human Vα24 T cells: lymphocytes of innate immunity [DOI]
50. 50 Generation of NK1.1 + T cell antigen receptor α/β + thymocytes associated with intact thymic structure [DOI]
51. 51 Myeloid-derived suppressor cells as regulators of the immune system [DOI]
52. 52 Exogenous and endogenous glycolipid antigens activate NKT cells during microbial infections [DOI]
53. 53 Tracking the Response of Natural Killer T Cells to a Glycolipid Antigen Using Cd1d Tetramers [DOI]
54. 54 A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells [DOI]
55. 55 Targeting natural killer cells and natural killer T cells in cancer [DOI]
56. 56 The Transcription Factor PLZF Directs the Effector Program of the NKT Cell Lineage [DOI]
57. 57 Identification of an IL-17–producing NK1.1neg iNKT cell population involved in airway neutrophilia [DOI]
58. 58 Structure-Activity Relationship of .alpha.-Galactosylceramides against B16-Bearing Mice [DOI]
59. 59 A transgenic mouse model for monitoring endoplasmic reticulum stress [DOI]
60. 60 Prevention of Autoimmunity by Targeting a Distinct, Noninvariant CD1d-reactive T Cell Population Reactive to Sulfatide [DOI]
61. 61 AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies [DOI]
62. 62 Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans [DOI]
63. 63 Presumed guilty: natural killer T cell defects and human disease [DOI]
64. 64 Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells [DOI]
65. 65 Harnessing invariant NKT cells in vaccination strategies [DOI]
66. 66 Vα24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages [DOI]
67. 67 Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signals [DOI]
68. 68 Identification of Bcl-6-dependent follicular helper NKT cells that provide cognate help for B cell responses [DOI]
69. 69 Bone Marrow Microenvironment in Multiple Myeloma Progression [DOI]
70. 70 Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications [DOI]
71. 71 The NKT cell system: bridging innate and acquired immunity [DOI]
72. 72 Agelasphins, novel α-galactosylceramides from the marine sponge Agelas mauritianus [DOI]
73. 73 A Phase I Study ofIn vitroExpanded Natural Killer T Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer [DOI]
74. 74 Peripheral blood IFN‐γ‐secreting Vα24 + Vβ11 + NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load [DOI]
75. 75 Human CD4+ CD25+ regulatory T cells suppress NKT cell functions.
76. 76 Combination therapy of in vitro‐expanded natural killer T cells and α‐galactosylceramide‐pulsed antigen‐presenting cells in patients with recurrent head and neck carcinoma [DOI]
77. 77 Natural Killer T Cells and Autoimmune Disease [DOI]
78. 78 Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma [DOI]
79. 79 Cutting Edge: Programmed Death-1/Programmed Death Ligand 1 Interaction Regulates the Induction and Maintenance of Invariant NKT Cell Anergy [DOI]
80. 80 Follicular Helper NKT Cells Induce Limited B Cell Responses and Germinal Center Formation in the Absence of CD4+ T Cell Help [DOI]
81. 81 Invariant natural killer T cells as sensors and managers of inflammation [DOI]
82. 82 Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide.
83. 83 Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice [DOI]
84. 84 The diverse functions of CD1d-restricted NKT cells and their potential for immunotherapy [DOI]
85. 85 A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model [DOI]
86. 86 BTB-ZF factors recruit the E3 ligase cullin 3 to regulate lymphoid effector programs [DOI]
87. 87 Regulation of multiple myeloma survival and progression by CD1d [DOI]
88. 88 CD1d-restricted T cell activation by nonlipidic small molecules [DOI]
89. 89 NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma [DOI]
90. 90 Accumulation of Activated Invariant Natural Killer T Cells in the Tumor Microenvironment after α-Galactosylceramide-Pulsed Antigen Presenting Cells [DOI]
91. 91 NKT cell costimulation: experimental progress and therapeutic promise [DOI]
92. 92 Glycolipids that Elicit IFN-γ-Biased Responses from Natural Killer T Cells [DOI]
93. 93 Structural and Functional Characterization of a Novel Nonglycosidic Type I NKT Agonist with Immunomodulatory Properties [DOI]
94. 94 Activated CD1d‐restricted natural killer T cells secrete IL‐2: innate help for CD4+CD25+ regulatory T cells? [DOI]
95. 95 Circulating Myeloid Dendritic Cells of Advanced Cancer Patients Result in Reduced Activation and a Biased Cytokine Profile in Invariant NKT Cells [DOI]
96. 96 Harnessing CD1d‐Restricted T Cells toward Antitumor Immunity in Humans [DOI]
97. 97 Preclinical Evaluation of Invariant Natural Killer T Cells in the 5T33 Multiple Myeloma Model [DOI]
98. 98 Attenuation of invariant Natural Killer T-cell anergy induction through intradermal delivery of α-galactosylceramide [DOI]
99. 99 Expansion of Lung Vα14 NKT Cells by Administration of α‐Galactosylceramide‐pulsed Dendritic Cells [DOI]
100. 100 Mouse models can predict cancer therapy [DOI]
101. 101 Tumor Angiogenesis and Metastasis — Correlation in Invasive Breast Carcinoma [DOI]
102. 102 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [DOI]
103. 103 What Is the Evidence That Tumors Are Angiogenesis Dependent? [DOI]
104. 104 CD1d-Restricted and TCR-Mediated Activation of V α 14 NKT Cells by Glycosylceramides [DOI]
105. 105 Multiple myeloma [DOI]
106. 106 The Biology of NKT Cells [DOI]
107. 107 Lysosomal Glycosphingolipid Recognition by NKT Cells [DOI]
108. 108 Invariant natural killer T cells: an innate activation scheme linked to diverse effector functions [DOI]
109. 109 Differential Tumor Surveillance by Natural Killer (Nk) and Nkt Cells [DOI]
110. 110 Functionally Distinct Subsets of CD1d-restricted Natural Killer T Cells Revealed by CD1d Tetramer Staining [DOI]
111. 111 Activation of Natural Killer T Cells by α-Galactosylceramide Rapidly Induces the Full Maturation of Dendritic Cells In Vivo and Thereby Acts as an Adjuvant for Combined CD4 and CD8 T Cell Immunity to a Coadministered Protein [DOI]
112. 112 The Regulatory Role of Vα14 NKT Cells in Innate and Acquired Immune Response [DOI]
113. 113 The Natural Killer T (NKT) Cell Ligand α-Galactosylceramide Demonstrates Its Immunopotentiating Effect by Inducing Interleukin (IL)-12 Production by Dendritic Cells and IL-12 Receptor Expression on NKT Cells [DOI]
114. 114 The Linkage of Innate to Adaptive Immunity via Maturing Dendritic Cells In Vivo Requires CD40 Ligation in Addition to Antigen Presentation and CD80/86 Costimulation [DOI]
115. 115 The BTB–zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions [DOI]
116. 116 Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (Trail) Contributes to Interferon γ–Dependent Natural Killer Cell Protection from Tumor Metastasis [DOI]
117. 117 A Reversible Defect in Natural Killer T Cell Function Characterizes the Progression of Premalignant to Malignant Multiple Myeloma [DOI]
118. 118 The Differentiation and Stress Response Factor XBP-1 Drives Multiple Myeloma Pathogenesis [DOI]
119. 119 Sustained expansion of NKT cells and antigen-specific T cells after injection of α-galactosyl-ceramide loaded mature dendritic cells in cancer patients [DOI]
120. 120 Sequential production of interferon-γ by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of α-galactosylceramide [DOI]
121. 121 Differential antitumor immunity mediated by NKT cell subsets in vivo [DOI]
122. 122 Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand α-Galactosylceramide [DOI]
123. 123 α-Galactosylceramide therapy for autoimmune diseases: prospects and obstacles [DOI]
124. 124 Increased Intratumor Vα24-Positive Natural Killer T Cells: A Prognostic Factor for Primary Colorectal Carcinomas [DOI]
125. 125 Invariant NKT cells and CD1d+ cells amass in human omentum and are depleted in patients with cancer and obesity [DOI]
126. 126 A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity [DOI]
127. 127 Invariant natural killer T cells direct B cell responses to cognate lipid antigen in an IL-21-dependent manner [DOI]
128. 128 Peroxisome-derived lipids are self antigens that stimulate invariant natural killer T cells in the thymus [DOI]
129. 129 Cross-Regulation between Type I and Type II NKT Cells in Regulating Tumor Immunity: A New Immunoregulatory Axis [DOI]
130. 130 NKT TCR Recognition of CD1d-α- C -Galactosylceramide [DOI]
131. 131 CD1d-restricted Recognition of Synthetic Glycolipid Antigens by Human Natural Killer T Cells [DOI]
132. 132 NKT Cell Stimulation with Glycolipid Antigen In Vivo: Costimulation-Dependent Expansion, Bim-Dependent Contraction, and Hyporesponsiveness to Further Antigenic Challenge [DOI]
133. 133 Angiogenesis in multiple myeloma [DOI]
134. 134 The immunoregulatory role of CD1d-restricted natural killer T cells in disease [DOI]
135. 135 Prevention of Diabetes in Nonobese Diabetic Mice Mediated by CD1d-Restricted Nonclassical NKT Cells [DOI]
136. 136 Diverse Endogenous Antigens for Mouse NKT Cells: Self-Antigens That Are Not Glycosphingolipids [DOI]
137. 137 Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy [DOI]
138. 138 Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro , Ex Vivo , and In Vivo in the 5T33MM Mouse Model [DOI]
139. 139 European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses [DOI]
140. 140 Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma [DOI]
141. 141 Invariant NKT Cells as Novel Targets for Immunotherapy in Solid Tumors [DOI]
142. 142 Invariant NKT cell anergy is induced by a strong TCR-mediated signal plus co-stimulation [DOI]
143. 143 CD1d-restricted “NKT” cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses? [DOI]
144. 144 NKT Cell-Dependent Regulation of Secondary Antigen-Specific, Conventional CD4+ T Cell Immune Responses [DOI]
145. 145 Regulation of Secondary Antigen-Specific CD8+ T-Cell Responses by Natural Killer T Cells [DOI]
146. 146 Regulation of Multiple Myeloma Survival and Progression by CD1d [DOI]
147. 147 European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses [DOI]

Cited by 3

Showing 1 of 3 known citations — external sources report more than can currently be individually listed.

Related research

• Effects of Breast Cancer Stem Cell Extract Primed Dendritic Cell Transplantation on Breast Cancer Tumor Murine Models — shares topic coverage
• Accessibility and Inclusivity of Chimeric Antigen Receptor T-cell Immunotherapy in Treating Hematological Malignancies — shares topic coverage
• The Effect of Immunotherapy on Some Immunological Parameters of Airway Allergic Patients in Province of Babylon/Iraq — shares topic coverage
• A Comprehensive Review on Cancer Immunotherapy in Veterinary Medicine — shares topic coverage
• Gene Editing in Cancer Immunotherapy: Mechanisms, Advancements, Limitations and Future Directions — shares topic coverage